EU Allows Pharma To Temporarily Prioritize Reporting For COVID-19 Adverse Events
Prioritization Allowed Until The Pandemic Is Resolved
Drug companies unable to continue with standard reporting of suspected adverse reactions to the EU pharmacovigilance database can temporarily prioritize their reporting activities to focus on COVID-19 related safety events.
